The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1681
ISSUE 1681
July 24, 2023
Issue 1681
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Tofersen (Qalsody) for ALS
July 24, 2023 (Issue: 1681)
Tofersen (Qalsody – Biogen), an intrathecally
administered antisense oligonucleotide, has received
accelerated approval from the FDA for treatment of
amyotrophic lateral sclerosis (ALS) in adults who
have a mutation in the superoxide dismutase...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.